PRODUCT INFORMATION



Urinary Prostacyclin Enzyme Immunoassay Kit

Catalog No. IB09652

96 Well Kit

Table of Contents

Description	Page	2
Introduction		2
Precautions		2
Materials Supplied		3
Storage		3
Materials Needed but Not Supplied		3
Sample Handling		4
Procedural Notes		5
Reagent Preparation		5
Assay Procedure		6
Calculation of Results		7
Typical Results		7
Typical Standard Curve		8
Typical Quality Control Parameters		8
Performance Characteristics		9
Sample Dilution Recommendations		11
References		11
Limited Warranty		12

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Description

The IBL-America Urinary Prostacyclin (UP) kit is a competitive immunoassay for the determination of Prostacyclin (PGI) breakdown products in urine. Please read the complete kit insert before performing this assay. The kit measures the two major breakdown products of PGI₂ in urine, 6-keto-Prostaglandin $F_{\lambda\alpha}$ (6k-PGF_{$\lambda\alpha$}) and 2,3-dinor-6-keto-Prostaglandin $F_{\lambda\alpha}$ (2,3d-6k-PGF_{$\lambda\alpha$}). The kit uses a polyclonal antibody that binds these two molecules with almost equal affinities. This antibody binds in a competitive manner, both the 6k-PGF_{$\lambda\alpha$} and 2,3d-6k-PGF_{$\lambda\alpha$} in the sample, or an alkaline phosphatase molecule which has 6k-PGF_{$\lambda\alpha$} covalently attached to it. After a simultaneous incubation at room temperature the excess reagents are washed away and substrate is added. After a short incubation time the color generated is read on a microplate reader at 405nm. The intensity of the bound yellow color is inversely proportional to the total concentration of 6k-PGF_{$\lambda\alpha$} and 2,3d-6k-PGF_{$\lambda\alpha$} in either standards or samples. The measured optical density of the 2,3d-6k-PGF_{$\lambda\alpha$} standards is used to calculate the concentration of both 6k-PGF_{$\lambda\alpha$} and 2,3d-6k-PGF_{$\lambda\alpha$} in the sample. For further explanation of the principles and practice of immunoassays please see the excellent books by Chard¹ or Tijssen².

Introduction

Prostacyclin (PGI₂) is involved in platelet aggregation, vasoconstriction, and reproductive functions ¹⁻³. PGI₂ has a half life of 60 minutes in plasma but only 2 to 3 minutes in buffer³. The production of PGI₂ is typically monitored by measurement of 6k-PGF_{$\lambda\alpha$} and 2,3d-6k-PGF_{$\lambda\alpha$}. 6-keto-PGF_{1α} is produced by the non-enzymatic hydration of PGI₂, and is further metabolized in urine to the 2,3-dinor derivative. A number of pharmaceuticals alter and/or inhibit the synthesis of PGI₂⁴. Methods to measure PGI₂ in urine typically involve HPLC⁵, gas chromatography/mass spectrometry⁶, or radioimmunoassay^{7,8} and enzyme immunoassay⁹ for 6k-PGF_{$\lambda\alpha$}. The conversion of PGI₂ into 6k-PGF_{$\lambda\alpha$} and 2,3d-6k-PGF_{$\lambda\alpha$} is shown below.

Precautions

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

- 1. Some kit components contain azide, which may react with lead or copper plumbing. When disposing of reagents always flush with large volumes of water to prevent azide build-up.
- 2. Stop Solution is a solution of trisodium phosphate. This solution is caustic; care should be taken in use.
- 3. The activity of the alkaline phosphatase conjugate is dependent on the presence of Mg^{2+} and Zn^{2+} ions. The activity of the conjugate is affected by concentrations of chelators (>10 mM) such as EDTA and EGTA.

4. The Urinary Prostacyclin standard provided is supplied in ethanolic buffer at a pH optimized to maintain integrity. Care should be taken handling this material because of the known and unknown effects of prostaglandins.

Materials Supplied

1. One 96 Well Donkey anti-Sheep IgG Plate

A plate using break-apart strips coated with donkey antibody specific to sheep IgG.

2. Urinary Prostacyclin Conj ugate, 6 mL

A blue solution of alkaline phosphatase conjugated with 6-keto-PGF₁₀.

3. Urinary Prostacyclin Antibody, 6 mL

A yellow solution of a sheep polyclonal antibody to $6k-PGF_{\lambda\alpha}$ and $2.3d-6k-PGF_{\lambda\alpha}$.

4. Assay Buffer, 30 mL

Tris buffered saline containing proteins and detergents and sodium azide as preservative.

5. Wash Buffer Concentrate, 30 mL

Tris buffered saline containing detergents.

6. Urinary Prostacyclin Standard, 0.5 mL

A solution of 100,000 pg/mL 2,3d-6k-PGF_{$\lambda \alpha$}.

7. p-Npp Substrate, 20 mL

A solution of p-nitrophenyl phosphate in buffer. Ready to use.

8. Stop Solution, 5 mL

A solution of trisodium phosphate in water. Keep tightly capped. Caution: Caustic.

- 9. Urinary Prostacyclin Assay Layout Sheet, 1 each
- 10. Plate Sealer, 1 each

Storage

All components of this kit are stable at 4 °C until the kit's expiration date.

Materials Needed But Not Supplied

- 1. Deionized or distilled water.
- 2. Precision pipets for volumes between 5 μ L and 1,000 μ L.
- 3. Repeater pipets for dispensing 50 µL and 200 µL.
- 4. Disposable beaker for diluting Wash Buffer.
- 5. Graduated cylinders.
- 6. A microplate shaker.
- 7. Adsorbent paper for blotting.
- 8. Microplate reader capable of reading at 405 nm, preferably with correction between 570 and 590 nm.

Sample Handling

The IBL-America Urinary Prostacyclin (UP) kit is compatible with 6k-PGF and 2,3d-6k-PGF samples in urine, tissue culture and buffer after dilution in Assay Buffer. Please refer to the Sample Recovery recommendations on page 11 for details of suggested dilutions. However, the end user **must verify** that the recommended dilutions are appropriate for their samples. **Samples containing sheep IgG may interfere with the assay.**

Samples in the majority of tissue culture media, including those containing fetal bovine serum, can also be read in the assay, provided the standards have been diluted into the tissue culture media instead of Assay Buffer. There will be small change in binding associated with running the standards and samples in media. Users should only use standard curves generated in media or buffer to calculate concentrations of 6k-PGF $_{\lambda\alpha}$ and 2,3d-6k-PGF $_{\lambda\alpha}$ in the appropriate matrix. For urine samples, prostaglandin synthetase inhibitors, such as, indomethacin or meclofenamic acid at concentrations up to 10 µg/mL should be added to the urine samples. Extraction may be necessary for measurement in some situations, a suitable extraction procedure is outlined below:

Materials Needed

- 1. Urinary Prostacyclin standard to accurately determine the extraction efficiency.
- 2. 2M hydrochloric acid, deionized water, ethanol, hexane and ethyl acetate.
- 3. 200 mg C₁₈ Reverse Phase Extraction Columns.

Procedure

- 1. Add sufficient Urinary Prostacyclin Standard to a typical sample for the determination of extraction efficiency.
- 2. Acidify the sample by addition of 2M HCl to pH of 3.5. Allow to sit at 4 °C for 15 minutes. Centrifuge samples in a microcentrifuge for 2 minutes to remove any precipitate.
- 3. Prepare the C_{18} reverse phase column by washing with 10 mL of ethanol followed by 10 mL of deionized water.
- 4. Apply the sample under a slight positive pressure to obtain a flow rate of about 0.5mL/minute. Wash the column with 10 mL of water, followed by 10 mL of 15% ethanol, and finally 10 mL hexane. Elute the sample from the column by addition of 10mL ethyl acetate.
- 5. If analysis is to be carried out immediately, evaporate samples under a stream of nitrogen. Reconstitute sample with at least 200 μ L of Assay Buffer. If analysis is to be delayed, store samples as the eluted ethyl acetate solutions at -80 °C until the immunoassay is to be run. Prior to analysis, evaporate the organic solvent under a stream of nitrogen and reconstitute as above.

Please refer to references 12-15 for details of extraction protocols.

Procedural Notes

- 1. Do not mix components from different kit lots or use reagents beyond the kit expiration date.
- 2. Allow all reagents to warm to room temperature for at least 30 minutes before opening.
- 3. Standards can be made up in either glass or plastic tubes.
- 4. Pre-rinse the pipet tip with reagent, use fresh pipet tips for each sample, standard and reagent.
- 5. Pipet standards and samples to the bottom of the wells.
- 6. Add the reagents to the side of the well to avoid contamination.
- 7. This kit uses break-apart microtiter strips, which allow the user to measure as many samples as desired. Unused wells must be kept desiccated at 4 °C in the sealed bag provided. The wells should be used in the frame provided.
- 8. Care must be taken to minimize contamination by endogenous alkaline phosphatase. Contaminating alkaline phosphatase activity, especially in the substrate solution, may lead to high blanks. Care should be taken not to touch pipet tips and other items that are used in the assay with bare hands.
- 9. Prior to addition of substrate, ensure that there is no residual wash Buffer in the wells. Any remaining wash Buffer may cause variation in assay results.

Reagent Preparation

1. Urinary Prostacyclin Standard

Allow the 100,000 pg/mL 2,3d-6k-PGF $_{\lambda\alpha}$ standard solution to warm to room temperature. Label five 12 x 75 mm glass tubes# 1 through# 5. Pipet 1mL of standard diluent (Assay Buffer or Tissue Culture Media) into tube# 1. Pipet 750 µL of standard diluent into tubes# 2 through # 5. Remove 20 µL of diluent from tube# 1. Add 20 µL of the 100,000 pg/mL stock standard to tube# 1. Vortex thoroughly. Add 250 µL of tube# 1 to tube# 2 and vortex thoroughly. Add 250 µL of tube# 2 to tube# 3 and vortex. Continue this for tubes# 4 through# 5.

The concentration of 2,3d-6k-PGF $_{\lambda\alpha}$ in tubes# 1 through#5 will be 2,000, 500, 125, 31.25 and 7.81 pg/mL respectively. See Urinary Prostacyclin Assay Layout Sheet for dilution details.

Diluted standards should be used within 60 minutes of preparation.

2. Conjugate 1: 10 Dilution for Total Activity Measurement

Prepare the Conjugate 1: 10 Dilution by diluting 50 μ L of the supplied Conjugate with 450 μ L of Assay Buffer. The dilution should be used within 3 hours of preparation. <u>This 1:10</u> dilution is intended for use in the Total Activity wells ONLY.

3. Wash Buffer

Prepare the Wash Buffer by diluting 5 mL of the supplied concentrate with 95 mL of deionized water. This can be stored at room temperature for 3 months.

Assay Procedure

Bring all reagents to room temperature for at least 30 minutes prior to opening.

All standards and samples should be run in duplicate.

- 1. Refer to the Assay Layout Sheet to determine the number of wells to be used and put any remaining wells with the desiccant back into the pouch and seal the ziploc. Store unused wells at 4 °C.
- 2. Pipet $100 \mu L$ of Standard Diluent (Assay Buffer or Tissue Culture Media) into the NSB and the Bo (0 pg/mL Standard) wells.
- 3. Pipet 100 µL of Standards #1 through #5 into the appropriate wells.
- 4. Pipet 100 μL of the Samples into the appropriate wells.
- 5. Pipet 50 μL of Assay Buffer into the NSB wells.
- 6. Pipet 50 μL of blue Conjugate into each well, except the Total Activity (TA) and β lank wells.
- 7. Pipet 50 µL of the yellow Antibody into each well, except the Blank, TA and NSB wells.
- **NOTE:** Every well used should be **Green** in color except the NSB wells which should be **Blue**. The Blank and TA wells are empty at this point and have no color.
- 8. Incubate the plate at room temperature on a plate shaker for 2 hours at ~ 500 rpm. The plate may be covered with the plate sealer provided, if so desired.
- 9. Empty the contents of the wells and wash by adding 400 μL of wash solution to every well. Repeat the wash 2 more times for a total of **3 washes.**
- 10. After the final wash, empty the wells and tap the plate dry on a lint free paper towel.
- 11. Add 5 μ L of the blue Conjugate 1:10 Dilution (see step 2, Reagent Preparation on page 5) to the TA wells.
- 12. Add 200 µL of the p-Npp Substrate solution to every well. Incubate at room temperature for 45 minutes without shaking.
- 13. Add 50 μ L of Stop Solution to every well. This stops the reaction and the plate should be read immediately.
- 14. B lank the plate reader against the B lank wells, read the optical density at 405 nm., preferably with correction between 570 and 590 nm. If the plate reader is not able to be blanked against the B lank wells, manually subtract the mean optical density of the B lank wells from all readings.

Calculation of Results

Several options are available for the calculation of the Urinary Prostacyclin (UP) concentration in the samples. We recommend that the data be handled by an immunoassay software package utilizing a 4 parameter logistic curve fitting program. If data reduction software is not readily available, the concentration of UP can be calculated as follows:

1. Calculate the average net Optical Density (OD) bound for each standard and sample by subtracting the average NSB OD from the Average OD bound:

Average Net OD = Average OD - NSB

2. Calculate the binding of each pair of standard wells as a percentage of the maximum binding wells (Bo), using the following formula:

Percent Bound = Net OD x 100

Net Bo OD

3. Using Logit-Log paper plot Percent Bound versus Concentration of UP for the standards. Approximate a straight line through the points. The concentration of UP in the unknowns can be determined by interpolation.

Typical Results

The results shown below are for illustration only and **should not** be used to calculate results from another assay.

C 1 -	Mean	Average	Percent Bound	Urinary Prostacyclin
<u>Sample</u>	OD (-B lank)	Net OD	<u> Bouilu</u>	$(\mathbf{pg}/\mathbf{mL})$
B lank OD	(0.137)			
TA	0.443	0.444		
NSB	-0.001	0.000	0.00%	
Во	1.117	1.118	100%	0
S1	0.069	0.070	6.3%	2,000
S2	0.154	0.155	13.9%	500
S3	0.372	0.373	33.4%	125
S4	0.746	0.747	66.8%	31.25
S5	0.969	0.970	86.8%	7.81
Unknown 1	0.241	0.240	22.2%	255
Unknown 2	0.665	0.666	61.5%	36.9

The Urinary Prostacyclin EIA kit measures both $6k\text{-PGF}_{\lambda\alpha}$ and $2,3d\text{-}6k\text{-PGF}_{\lambda\alpha}$ in most samples. If the levels of either $6k\text{-PGF}_{\lambda\alpha}$ or $2,3d\text{-}6k\text{-PGF}_{\lambda\alpha}$ are to be determined independently, then the samples should also be measured in the IBL-America $6k\text{-PGF}_{\lambda\alpha}$ EIA kit. This kit measures 6k-PGF with $6k\text{-PGF}_{\lambda\alpha}$ minimal cross reactivity (3.17%) to 2,3d-6k-PGF. By measuring the same samples in both kits the levels of either $6k\text{-PGF}_{\lambda\alpha}$ or 2,3d-6k-PGF can be determined if the concentrations of PGI metabolites are approximately equal. The following formulas can be used to calculate the actual concentration of each analyte.

Let the actual concentration of 6k-PGF $_{\lambda\alpha}$ = A. Let the actual concentration of 2,3d-6k-PGF $_{\lambda\alpha}$ = B.


A = 1.029 x [Measured 6-k Conc. - (0.0317 x Measured UP Conc.)]

B = 1.029 x [Measured UP Conc. - (0.8914 x Measured 6-k Conc.)]

Please Note: These calculations only apply to situations where 6k-PGF $_{\lambda\alpha}$ or 2.3d-6k-PGF $_{\lambda\alpha}$ concentrations are approximately equal in the measured samples, and the determinations of both 6k-PGF $_{\lambda\alpha}$ and Urinary Prostacyclin levels occur within the accurate part of the assay standard curves.

Typical Standard Curve

A typical standard curve is shown below. This curve **must not** be used to calculate Urinary Prostacyclin concentrations; each user must run a standard curve for each assay.



Typical Quality Control Parameters

Total Activity Added = 0.443x100= 44.3

% NSB = 0.0% % Bo / TA = 2.5%

Quality of Fit = 1.0000 (Calculated from 4 parameter logistic curve fit)

20% Intercept = 270.0 pg/mL 50% Intercept = 62.9 pg/mL 80% Intercept = 14.6 pg/mL

Performance Characteristics

The following parameters for this kit were determined using the guidelines listed in the National Committee for Clinical Laboratory Standards (NCCLS) Evaluation Protocols¹⁶.

Sensitivity

Sensitivity was calculated in Assay Buffer by determining the average optical density bound for sixteen (16) wells run as Bo, and comparing to the average optical density for sixteen (16) wells run with Standard \sharp 5. The detection limit was determined as the concentration of 2,3d-6k-PGF_{$\lambda\alpha$} measured at two (2) standard deviations from the zero along the standard curve.

Average Optical Density for the Bo = 0.731 ± 0.016 (2.18%) Average Optical Density for Standard #5 = 0.693 ± 0.020 (2.94%)

Delta Optical Density (0-7.81 pg/mL) = 0.038

2 SD's of the Zero Standard = 2 x 0.016 = 0.032

Sensitivity = $\frac{0.032}{0.038}$ x 7.81 pg/mL = **6.58 pg/mL**

Linearity

A sample containing 400 pg/mL 2,3d-6k-PGF $_{\lambda\alpha}$ was diluted 6 times 1:2 in the kit Assay Buffer and measured in the assay. The data was plotted graphically as actual 2,3d-6k-PGF $_{\lambda\alpha}$ concentration versus measured 2,3d-6k-PGF $_{\lambda\alpha}$ concentration.

The line obtained had a slope of 1.069 and a correlation coefficient of 0.995.

Precision

Intra-assay precision was determined by taking samples containing low, medium and high concentrations of 2,3d-6k-PGF $_{\lambda\alpha}$ and running these samples multiple times (n= 24) in the same assay. Inter-assay precision was determined by measuring three samples with low, medium and high concentrations of 2,3d-6k-PGF $_{\lambda\alpha}$ in multiple assays (n= 8).

The precision numbers listed on the next page represent the percent coefficient of variation for the concentrations of 2,3d-6k-PGF_{$\lambda\alpha$} determined in these assays as calculated by a 4 parameter logistic curve fitting program.

	2,3d-6k-PGF $_{\lambda\alpha}$ (pg/mL)	Intra-assay % CV	Inter-assay <u>% CV</u>
Low	23	9.1	
Medium	66	3.4	
High	200	2.9	
Low	23		9.6
Medium	72		5.4
High	223		3.4

Cross Reactivities

The cross reactivities for a number of related eicosanoid compounds were determined by dissolving the cross reactant (purity checked by N.M.R. and other analytical methods) in Assay B uffer at concentrations from 500,000 to 39 pg/mL. These samples were then measured in the UP assay, and the measured concentration at 50% B/B o calculated. The % cross reactivity was calculated by comparison with the actual concentration of cross reactant in the sample and expressed as a percentage.

<u>Antigen</u>	Cross Reactivity
2,3-dinor-6-keto-PGF $_{\lambda\alpha}$	100%
6-keto-PGF $_{\lambda\alpha}$	89.14%
$PGF_{\lambda lpha}$	13.21%
$PGF_{2\alpha}^{n}$	4.99%
$13,14$ dihydro-PGF _{$\lambda\alpha$}	2.55%
15-keto-PGF _{2a}	0.32%
PGE ₁	0.08%
PGD,	0.03%
$6,15$ -diketo-13,14 dihydro-PGF _{$\lambda\alpha$}	0.03%
PGB 1	0.01%
PGE ₂	0.01%
PGA_2	0.01%
TX B 2	0.01%

Sample Recoveries

Please refer to pages 4 and 5 for Sample Handling recommendations and Standard preparation.

UP concentrations were measured in tissue culture media (TCM) and urine. PGI₂ was spiked into the undiluted samples of these media which were then diluted with the appropriate diluent and assayed in the kit. The following results were obtained:

<u>Sample</u>	% Recovery*	Recommended Dilution*
Tissue Culture Media	109.2	1:2
Human Urine	101.9	1:10

^{*} See Sample Handling instructions on page 4 for details.

Ref erences

- 1. T. Chard, "An Introduction to Radioimmunoassay & Related Techniques 4th Ed.", (1990) Amsterdam: Elsevier.
- 2. P. Tijssen, "Practice & Theory of Enzyme Immunoassays", (1985) Amsterdam: Elsevier.
- 3. A.S. Nies, <u>Clin.Pharmacol. Ther.</u>, (1986) <u>39</u>: 481.
- 4. K.L. B righam, et al., <u>Prostaglandins and the Cardiovascular System</u>, (1982) New York: Raven Press.
- 5. O. Ylikorkala & U.M. Makila, <u>Am. J. Obstet. Gynecol.</u>, (1985) <u>152</u>: 318.
- 6. J.M. Gerrard, <u>Can. J. Physiol. Pharmacol.</u>, (1989) <u>67</u>: 922.
- 7. W.S. Powell, <u>Anal. B iochem.</u>, (1987) <u>164</u>: 117.
- 8. C. Chiabrando, et al., J. Chromatography, (1989) 495: 1.
- 9. A. Riutta, et al., Anal. B iochem., (1994) 220: 351.
- 10. W. Schramm, et al., Clin. Chem., (1990) 36: 509.
- 11. T. Tonai, et al., <u>B iochim. B iophys</u>, Acta, (1985) <u>836</u>: 335.
- 12. K. Green, et al., Anal. B iochem., (1973) <u>54</u>: 434.
- 13. J. Frolich, et al., J. Clin. Invest., (1975) 55: 763.
- 14. J.E. Shaw & P.W. Ramwell, Meth. B iochem. Anal., (1969) 17: 325.
- 15. K. Green, et al., Adv. Prostaglandin & Thromboxane Res., (1978) 5: 15.
- 16. National Committee for Clinical Laboratory Standards Evaluation Protocols, SC1, (1989) Villanova, PA: NCCLS.

LIM ITED WARRANTY

IBL-America warrants that at the time of shipment this product is free from defects in materials and workmanship. This warranty is in lieu of any other warranty expressed or implied, including but not limited to, any implied warranty of merchantability or fitness for a particular purpose.

IBL-America must be notified of any breach of this warranty within 48 hours of receipt of the product. No claim shall be honored if IBL-America is not notified within this time period, or if the product has been stored in any way other than outlined in this publication. The sole and exclusive remedy of the customer for any liability based upon this warranty is limited to the replacement of the product, or refund of the invoice price of the goods.

For more details concerning the information within this kit insert, or to order any IBL-America products, please call (763) 780-2955 between 8:00 a.m. and 5:00 p.m. CST.

Fax: 1 (763) 780-2988

Material Safety Data Sheet (MSDS) available on our website or by fax.

Immuno-Biological **Telephone:** (763) 780-2955 Laboratories, Inc.

8201 Central Ave NE

Suite P Minneapolis, MN

E-mail: ibl@ibl-america.com Website: www.ibl-america.com 55432 USA

December 8, 2004

